Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 5/20 | 0.73 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.71 |
| ▸ | KDR | P35968 | 5/20 | 0.71 |
| ▸ | LCK | P06239 | 5/20 | 0.71 |
| ▸ | JAK3 | P52333 | 4/20 | 0.71 |
| ▸ | TEK | Q02763 | 3/20 | 0.71 |
| ▸ | ABL1 | P00519 | 2/20 | 0.71 |
| ▸ | BRAF | P15056 | 9/20 | 0.61 |
| ▸ | KIT | P10721 | 2/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.61 |
| ▸ | LYN | P07948 | 1/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.61 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.61 |
| ▸ | RAF1 | P04049 | 6/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932220 | 0.92 | DDR2 (0.73) | DDR2MAPK14KDRLCKJAK3 | |
| SCHEMBL2883679 | 0.89 | DDR2 (0.70) | DDR2MAPK14KDRLCKJAK3 | |
| SCHEMBL13198183 | 0.88 | KDR (0.76) | DDR2MAPK14KDRLCKJAK3 | |
| SCHEMBL13198190 | 0.85 | KDR (0.73) | DDR2MAPK14KDRLCKJAK3 | |
| SCHEMBL13198179 | 0.85 | DDR2 (1.00) | DDR2MAPK14KDRLCKJAK3 | |
| SCHEMBL13198189 | 0.85 | KDR (0.77) | DDR2MAPK14KDRLCKJAK3 | |
| SCHEMBL3934490 | 0.84 | MAPK14 (0.76) | DDR2MAPK14KDRLCKJAK3 | |
| SCHEMBL16037428 | 0.83 | BRAF (0.67) | DDR2MAPK14KDRLCKJAK3 | |
| SCHEMBL13198172 | 0.83 | BRAF (0.74) | DDR2MAPK14KDRLCKJAK3 | |
| SCHEMBL14244705 | 0.83 | ABL1 (1.00) | MAPK14KDRLCKJAK3TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | NOVARTIS AG | 2009-12-10 | — | — | US | claimed |
| EP-2043638-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2009-04-08 | — | — | EP | claimed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | claimed |
| WO-2008008821-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | claimed |
| EP-1778640-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-05-02 | — | — | EP | claimed |
| WO-2006015859-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | claimed |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2006-02-16 | — | — | US | claimed |
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | NOVARTIS AG | 2009-12-10 | — | — | US | disclosed |
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | NOVARTIS AG | 2009-12-10 | — | — | US | disclosed |
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | NOVARTIS AG | 2009-12-10 | — | — | US | disclosed |
| EP-2043638-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| WO-2008008821-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008821-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| EP-1778640-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015859-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | MAP3K1, MAP3K20, MAP3K2 | DDR2 1243/4885MAPK14 43/4885KDR 872/4885 |
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | EPHB3, EPHB2, EPHB1 | DDR2 1917/4885MAPK14 2431/4885KDR 1129/4885 |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | ABL1, ERBB2, EPHB2 | DDR2 752/4885MAPK14 88/4885KDR 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.